Trial: 202102117

The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib

Phase

III

Principal Investigator

Bagegni, Nusayba

Disease Site

Breast

Learn more about this study at: clinicaltrials.gov